252 related articles for article (PubMed ID: 18032947)
1. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
Wu J; Rosenbaum E; Begum S; Westra WH
Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
[TBL] [Abstract][Full Text] [Related]
2. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure.
Karram S; Novy M; Saroufim M; Loya A; Taraif S; Houreih MA; Rauscher B; Habib RH; Oberkanins C; Khalifeh I
Am J Dermatopathol; 2013 Jun; 35(4):412-8. PubMed ID: 23051629
[TBL] [Abstract][Full Text] [Related]
3. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
Cohen Y; Rosenbaum E; Begum S; Goldenberg D; Esche C; Lavie O; Sidransky D; Westra WH
Clin Cancer Res; 2004 May; 10(10):3444-7. PubMed ID: 15161700
[TBL] [Abstract][Full Text] [Related]
4. T1799A BRAF mutations in conjunctival melanocytic lesions.
Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
[TBL] [Abstract][Full Text] [Related]
5. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
6. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
7. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
8. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.
Ichii-Nakato N; Takata M; Takayanagi S; Takashima S; Lin J; Murata H; Fujimoto A; Hatta N; Saida T
J Invest Dermatol; 2006 Sep; 126(9):2111-8. PubMed ID: 16691193
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.
Kanitakis J; Baldassini S; Lora V; Euvrard S
Eur J Dermatol; 2010; 20(2):167-71. PubMed ID: 19919912
[TBL] [Abstract][Full Text] [Related]
10. BRAF analysis on a spectrum of melanocytic neoplasms: an epidemiological study across differing UV regions.
Saroufim M; Habib R; Karram S; Youssef Massad C; Taraif S; Loya A; Houreih MA; Sheikh SS; Amr SS; Satti M; Oberkanins C; Khalifeh I
Am J Dermatopathol; 2014 Jan; 36(1):68-73. PubMed ID: 23782679
[TBL] [Abstract][Full Text] [Related]
11. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
12. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
Decarlo K; Yang S; Emley A; Wajapeyee N; Green M; Mahalingam M
Hum Pathol; 2010 Jun; 41(6):886-94. PubMed ID: 20233623
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutations in conjunctival melanoma.
Gear H; Williams H; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
17. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
[TBL] [Abstract][Full Text] [Related]
18. Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population.
Wu D; Wang M; Wang X; Yin N; Song T; Li H; Yu J; Wang DM; Zhao Z
Am J Dermatopathol; 2011 Jun; 33(4):341-4. PubMed ID: 21430505
[TBL] [Abstract][Full Text] [Related]
19. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
20. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
